Observed Signal · Sep 16, 2026 · Policy Update · Source: Astral Codex Ten · Impact: 2/5 · Sentiment: Positive

AI Superforecasting Could Transform FDA Drug Approvals

Executive Signal Summary

This guest post on Astral Codex Ten argues that AI superforecasting could transform FDA drug approval processes. The author, Josh Morrison of 1DaySooner, proposes a gradual implementation where the FDA first adds quantitative forecasts to existing decisions, such as predicting patient deaths or drug efficacy during trials. These forecasts would be checked against real-world data, eventually becoming public and then legal triggers for automatic approvals or trial progression. The post discusses the potential for reduced subjectivity, increased predictability for drug developers, and more efficient trials, while acknowledging the need for validation and calibration before full adoption.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This opinion piece discusses AI superforecasting for FDA reform, which is related to AI technologies but is not directly about AdTech/MarTech, and it's a proposal rather than a concrete development.

MARKET SIGNALS

Track AI & Technology Signals & Market Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • Artificial intelligence superforecasters are described as becoming widely available within a few years.
  • Josh Morrison, from advocacy group 1DaySooner, proposes using AI forecasting at the US FDA.
  • The proposal includes a gradual three-stage implementation: adding forecasts to existing decisions, making forecasts public, and using them as legal triggers.
  • The FDA's Sentinel program uses real-world evidence to identify safety signals among approved products.
  • The Trump administration announced a pilot program to speed up phase 1 clinical trials under Operation Trialblazer.
  • In 2021, the FDA faced criticism for its approval of Biogen's Alzheimer's drug Aduhelm.

Ontology Mapping & Concepts

Large Language Models (LLM) & AI#AI superforecasting#Quantitative regulatory triggers
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: Astral Codex Ten•Published: Sep 16, 2026
Original Coverage Title: “AI Superforecasting Should Transform The FDA”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

AI in Drug DiscoveryNov 13, 2026

AI to Supercharge Big Pharma Economics

The article from a16z argues that AI will fundamentally transform the pharmaceutical industry by improving drug discovery and development economics. It highlights the industry's current 'hits business' R&D model, where the average drug costs nearly $2B and takes 13 years to develop, contrasting it with the potential for AI to increase success rates and reduce timelines. The piece points to pharma giants like Eli Lilly, with a $1T market cap and strong GLP-1 portfolio sales, as evidence of the sector's software-like scale. It outlines how AI, including reasoning models, diffusion-based molecule generation, and scale laws, is enabling new capabilities. The author also discusses emerging startup categories such as data providers, predictive model builders, and full-stack biotech companies, alongside notable partnerships like Isomorphic Labs with Novartis and Eli Lilly, and Chai Discovery with Pfizer, suggesting a commercial momentum that could rival big software.

Read assessment
AISep 10, 2026

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

Read assessment
AI RegulationOct 7, 2026

AI Godfather Hinton Urges FDA-Style Approval for AI Models

Nobel laureate Geoffrey Hinton, often called the 'Godfather of AI', recommends that AI models undergo an approval process similar to that of drugs before release. In a podcast, he suggested that AI companies should have to convince a regulatory authority of their products' safety, akin to the FDA's process, which he notes is costly and time-consuming. This comes amid warnings from Hinton, Yoshua Bengio, and 20 other AI experts about a possible 'intelligence explosion' where AI systems improve themselves, risking humanity's control. Hinton argues that exponential progress could lead to a drastic worsening within one or two years. His call for stricter regulation contrasts with the current US approach, which relies on self-regulation rather than binding rules, despite a letter from 1,400 researchers and requests from major AI companies like Anthropic and OpenAI for more oversight.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for AI & Technology in your Watchlist briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context